Table 1.

Demographic and clinical data of the subjects

HCNfvPPASvPPALvPPA
Age65.3 (3.9)67.3 (5.7)61.4 (5.6)63.6 (7.1)
Sex (F/M)13/86/35/34/4
Education17.3 (2.2)15.1 (2.8)16.0 (1.5)16.1 (3.2)
Disease durationNA4.2 (1.8)5.4 (3.2)5.1 (4.4)
MMSE (30)29.5 (0.7)25.1 (3.8)*24.4 (5.1)*23.8 (6.4)*
CDRNA0.5 (0.4)0.8 (0.5)0.6 (0.2)
Speech and language evaluation
    WAB-Spontaneous Speech Fluency (10)0.0 (0.0)6.1 (1.8)*,b8.6 (0.9)8.1 (1.5)
    WAB Rep Tot (100)NA78.5 (10.2)84.1 (17.9)71.8 (17.1)
    Boston Naming Test (15)14.6 (0.5)12.2 (2.0)6.2 (5.8)*a,c9.6 (5.0)*
    MSE Apraxia of Speech Rating (0–7)0.0 (0.0)2.9 (1.3)*b,c0.0 (0.0)0.5 (1.1)
    MSE Dysarthria Rating (0–7)0.0 (0.0)2.1 (2.1)*b0.0 (0.0)0.38 (1.1)
    Speech Production Score (1)0.0 (0.0)0.63 (0.1)b,c0.92 (0.1)0.87 (0.1)
    WAB Sequential Commands (80)NA71.3 (8.5)65.3 (18.3)68.3 (11.8)
    Pyramids and Palm Trees–Picture Version (52)NA49.6 (1.4)41.3 (7.2)a,c50.4 (1.2)
    Peabody Picture Vocabulary Test–Revised (16)NA14.3 (1.3)6.5 (5)a,c13.3 (2.5)
Other cognitive domains
    Benson Figure Copy (17)15.0 (1.4)14.9 (1.8)15.6 (0.9)14.9 (1.1)
    Benson Figure Delay Recall (17)11.5 (2.8)9.3 (3.5)7.0 (5.2)*7.3 (2.9)
    Digit Span Backwards6.1 (1.4)3.1 (1.3)*b5.1 (1.1)3.3 (1.0)*b
  • Values are reported as mean (SD).

  • *Significant differences compared with controls at p < 0.05.

  • an Significant differences from nonfluent variants at p < 0.05.

  • bn Significant differences from semantic variants at p < 0.05.

  • cn Significant differences from logopenic variants at p < 0.05.